Friday, June 1, 2012

Kalorama Vaccine Estimates Published in Business Week

Kalorama's estimated numbers for vaccine sales are cited in an article in Business Week regarding the change in leadership at Takeda Pharmaceuticals.  The basic message: mixing a high-growth product like vaccines with high-growth emerging markets is  a winning strategy.  

The worldwide vaccines market excluding North America, European Union members and Japan, probably expanded 11 percent to $6.78 billion last year and will increase about 10 percent annually for the next five years, researcher Kalorama Information said.

Slightly higher growth than developed markets at 8-9%.  The citation is timely because Tadataka “Tachi” Yamada, the new head of Takeda, wants to direct efforts to these countries.